The observation that down-regulating by metformin the activation of STAT3 and the overexpression of miR-21 in vivo limited lipid accumulation and liver damage identifies miR-21 and STAT3 inhibition as new promising pharmacological targets for treating NAFLD. Here, STAT3 is linked to metabolic dysfunction-associated steatotic liver disease.